Skip Nav Destination
Neonatal GATA1 mutant clones under the radar
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia
Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model
Issue Archive
December 5 2013
Table of Contents
INSIDE BLOOD
CLINICAL TRIALS & OBSERVATIONS
Neonatal GATA1 mutant clones under the radar
Clinical Trials & Observations
BLOOD WORK
PLENARY PAPER
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Edward A. Copelan,Betty K. Hamilton,Belinda Avalos,Kwang Woo Ahn,Brian J. Bolwell,Xiaochun Zhu,Mahmoud Aljurf,Koen van Besien,Christopher Bredeson,Jean-Yves Cahn,Luciano J. Costa,Marcos de Lima,Robert Peter Gale,Gregory A. Hale,Joerg Halter,Mehdi Hamadani,Yoshihiro Inamoto,Rammurti T. Kamble,Mark R. Litzow,Alison W. Loren,David I. Marks,Eduardo Olavarria,Vivek Roy,Mitchell Sabloff,Bipin N. Savani,Matthew Seftel,Harry C. Schouten,Celalettin Ustun,Edmund K. Waller,Daniel J. Weisdorf,Baldeep Wirk,Mary M. Horowitz,Mukta Arora,Jeff Szer,Jorge Cortes,Matt E. Kalaycio,Richard T. Maziarz,Wael Saber
PLENARY PAPER
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Clinical Trials & Observations
Christopher Bredeson,Jennifer LeRademacher,Kazunobu Kato,John F. DiPersio,Edward Agura,Steven M. Devine,Frederick R. Appelbaum,Marcie R. Tomblyn,Ginna G. Laport,Xiaochun Zhu,Philip L. McCarthy,Vincent T. Ho,Kenneth R. Cooke,Elizabeth Armstrong,Angela Smith,J. Douglas Rizzo,Jeanne M. Burkart,Marcelo C. Pasquini
PERSPECTIVES
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Clinical Trials & Observations
Lisa K. Hicks,Harriet Bering,Kenneth R. Carson,Judith Kleinerman,Vishal Kukreti,Alice Ma,Brigitta U. Mueller,Sarah H. O'Brien,Marcelo Pasquini,Ravindra Sarode,Lawrence Solberg, Jr,Adam E. Haynes,Mark A. Crowther
REVIEW ARTICLE
REVIEW SERIES
CLINICAL TRIALS AND OBSERVATIONS
GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia
Clinical Trials & Observations
Irene Roberts,Kate Alford,Georgina Hall,Gaetan Juban,Helen Richmond,Alice Norton,Grant Vallance,Kelly Perkins,Emanuele Marchi,Simon McGowan,Anindita Roy,Gillian Cowan,Mark Anthony,Amit Gupta,John Ho,Sabita Uthaya,Anna Curley,Shree Vishna Rasiah,Timothy Watts,Richard Nicholl,Alison Bedford-Russell,Raoul Blumberg,Angela Thomas,Brenda Gibson,Chris Halsey,Pek-Wan Lee,Sunit Godambe,Connor Sweeney,Neha Bhatnagar,Anne Goriely,Peter Campbell,Paresh Vyas,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group,on behalf of the Oxford-Imperial Down Syndrome Cohort Study Group
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
IL-21 signalling via STAT3 primes human naïve B cells to respond to IL-2 to enhance their differentiation into plasmablasts
Lucinda J. Berglund,Danielle T. Avery,Cindy S. Ma,Leen Moens,Elissa K. Deenick,Jacinta Bustamante,Stephanie Boisson-Dupuis,Melanie Wong,Stephen Adelstein,Peter D. Arkwright,Rosa Bacchetta,Liliana Bezrodnik,Harjit Dadi,Chaim M. Roifman,David A. Fulcher,John B. Ziegler,Joanne M. Smart,Masao Kobayashi,Capucine Picard,Anne Durandy,Matthew C. Cook,Jean-Laurent Casanova,Gulbu Uzel,Stuart G. Tangye
LYMPHOID NEOPLASIA
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
Pau Abrisqueta,Neus Villamor,María José Terol,Eva González-Barca,Marcos González,Christelle Ferrà,Eugenia Abella,Julio Delgado,Jose A. García-Marco,Yolanda González,Felix Carbonell,Secundino Ferrer,Encarna Monzó,Isidro Jarque,Ana Muntañola,Mireia Constants,Lourdes Escoda,Xavier Calvo,Sabela Bobillo,José Bruno Montoro,Emili Montserrat,Francesc Bosch
Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model
Brief Report
Valeria Lascano,Marco Guadagnoli,Jan G. Schot,Dieuwertje M. Luijks,Jeroen E. J. Guikema,Katherine Cameron,Michael Hahne,Steven Pals,Erik Slinger,Thomas J. Kipps,Marinus H. J. van Oers,Eric Eldering,Jan Paul Medema,Arnon P. Kater
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSPLANTATION
Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation
F. Lennie Wong,Liton Francisco,Kayo Togawa,Heeyoung Kim,Alysia Bosworth,Liezl Atencio,Cara Hanby,Marcia Grant,Fouad Kandeel,Stephen J. Forman,Smita Bhatia
VASCULAR BIOLOGY
Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature
Xabier L. Aranguren,Xabier Agirre,Manu Beerens,Giulia Coppiello,Maialen Uriz,Ine Vandersmissen,Mohammed Benkheil,Joaquin Panadero,Natalia Aguado,Alberto Pascual-Montano,Victor Segura,Felipe Prósper,Aernout Luttun
-
Cover Image
Cover Image
![issue cover]()
Photomicrograph of erythrocyte morphologic abnormalities on a blood smear from a neonate with Down syndrome showing dyserythropoietic normoblasts and basophilic stippling. Trilineage dysplasia of peripheral blood cells is seen in almost all neonates with Down syndrome. See the article by Roberts et al on page 3908.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
